Recognition of early and late stages of bladder cancer using metabolites and machine learning

Valentina L. Kouznetsova1,2, Elliot Kim3, Eden Romm4, Alan Zhu3, Igor F. Tsigelny2,1,4
1Moores Cancer Center, UC San Diego, San Diego, USA
2San Diego Supercomputer Center, UC San Diego, San Diego, USA
3REHS Program UC San Diego, San Diego, USA
4CureMatch Inc., San Diego, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Aguer, C., Gambarotta, D., Mailloux, R. J., Moffat, C., Dent, R., McPherson, R., et al. (2011). Galactose enhances oxidative metabolism and reveals mitochondrial dysfunction in human primary muscle cells. PLoS ONE, 6(12), e28536.

Amelio, I., Cutruzzolá, F., Antonov, A., Agostini, M., & Melino, G. (2014). Serine and glycine metabolism in cancer. Trends in Biochemical Sciences, 39(4), 191–198.

Brown, D. G., Rao, S., Weir, T. L., O’Malia, J., Bazan, M., Brown, R. J., et al. (2016). Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer & Metabolism, 4, 11.

Burger, M., Catto, J. W., Dalbagni, G., Grossman, H. B., Herr, H., Karakiewicz, P., et al. (2013). Epidemiology and risk factors of urothelial bladder cancer. European Urology, 63(2), 234–241.

Cao, M., Zhao, L., Chen, H., Xue, W., & Lin, D. (2012). NMR-based metabolomic analysis of human bladder cancer. Analytical Sciences, 28(5), 451–456.

Chen, W. Y., Wu, F., You, Z. Y., Zhang, Z. M., Guo, Y. L., & Zhong, L. X. (2015). Analyzing the differentially expressed genes and pathway cross-talk in aggressive breast cancer. Journal of Obstetrics and Gynaecology, 41(1), 132–140.

Chen, T., Xie, G., Wang, X., Fan, J., Qiu, Y., Zheng, X., et al. (2011). Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Molecular and Cellular Proteomics, 10(7), M110.004945.

Cheng, X., Liu, X., Liu, X., Guo, Z., Sun, H., Zhang, M., et al. (2018). Metabolomics of non-muscle invasive bladder cancer: biomarkers for early detection of bladder cancer. Frontiers in Oncology, 8, 494.

Cheng, J., Zheng, G., Jin, H., & Gao, X. (2017). Towards tyrosine metabolism in esophageal squamous cell carcinoma. Combinatorial Chemistry & High Throughput Screening, 20(2), 133–139.

Chong, J., Soufan, O., Li, C., Caraus, I., Li, S., Bourque, G., et al. (2018). MetaboAnalyst 4.0: Towards more transparent and integrative metabolomics analysis. Nucleic Acids Research, 46(W1), W486–W494.

Coloff, J. L., Murphy, J. P., Braun, C. R., Harris, I. S., Shelton, L. M., Kami, K., et al. (2016). Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. Cell Metabolism, 23(5), 867–880.

Conde, V. R., Oliveira, P. F., Nunes, A. R., Rocha, C. S., Ramalhosa, E., Pereira, J. A., et al. (2015). The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism. Experimental Cell Research, 335(1), 91–98.

Córdoba-Chacón, J., Gahete, M. D., Pozo-Salas, A. I., Castaño, J. P., Kineman, R. D., & Luqu, E. R. M. (2013). Endogenous somatostatin is critical in regulating the acute effects of l-arginine on growth hormone and insulin release in mice. Endocrinology, 154(7), 2393–2398.

Ferdosi, S., Ho, T. H., Castle, E. P., Stanton, M. L., Borges, C. H., & Ahmad, A. (2018). Behavior of blood plasma glycan features in bladder cancer. PLoS One, 13(7), e0201208.

Feron, O. (2009). Pyruvate into lactate and back: From the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiotherapy and Oncology, 92(3), 329–333.

Frank, E., Hall, M. A., & Witten, I. H. (2016). The WEKA workbench. Online Appendix for Data Mining: Practical Machine Learning Tools and Techniques (4th ed.). Morgan Kaufmann Series in Data Managing Systems. San Francisco, Calif., USA: Morgan Kauffman Publishers, Inc. https://www.cs.waikato.ac.nz/ml/weka/Witten_et_al_2016_appendix.pdf .

Gallo, E. F., & Iadecola, C. (2011). Neuronal nitric oxide contributes to neuroplasticity-associated protein expression through cGMP, protein kinase G, and extracellular signal-regulated kinase. Journal of Neuroscience, 31(19), 6947–6955.

Gamagedara, S., Shi, H., & Ma, Y. (2012). Quantitative determination of taurine and related biomarkers in urine by liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 402(2), 763–770.

Garcia-Bermudez, J., Baudrier, L., La, K., Zhu, X. G., Fidelin, J., Sviderskiy, V. O., et al. (2018). Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nature Cell Biology, 20(7), 775–781.

Grau, M., Pauly, S., Ali, J., Walpurgis, K., Thevis, M., Bloch, W., et al. (2013). RBC-NOS-dependent S-nitrosylation of cytoskeletal proteins improves RBC deformability. PLoS ONE, 8(2), e56759.

Hall, M., Frank, E., Holmes, G., Pfahringer, B., Reutemann, P., & Witten, I. H. (2009). The WEKA data mining software: An update. ACM SIGKDD Explorations Newsletter, 11(1), 10–18.

IPA Fall 2018 Release Is Here! Now with faster functionalities and more than 49,000 datasets available for Analysis Match! https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis .

Issaq, H. J., Nativ, O., Waybright, T., Luke, B., Veenstra, T. D., Issaq, E. J., et al. (2018). Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. Journal of Urology, 179(6), 2422–2426.

Jin, X., Yun, S. J., Jeong, P., Kim, I. Y., Kim, W. J., & Park, S. (2014). Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget, 5(6), 1635–1645.

Kajiwara, A., Tsuchiya, Y., Takata, T., Nyunoya, M., Nozaki, N., Ihara, H., et al. (2013). Nitric oxide enhances increase in cytosolic Ca(2 +) and promotes nicotine-triggered MAPK pathway in PC12 cells. Nitric Oxide, 34, 3–9.

Karin, M. (1995). The regulation of AP-1 activity by mitogen-activated protein kinases. Journal of Biological Chemistry, 270(28), 16485–16486.

Kim, K., Taylor, S. L., Ganti, S., Guo, L., Osier, M. V., & Weiss, R. H. (2011). Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS: A Journal of Integrative Biology, 15(5), 293–303.

Kim, W. T., Yun, S., Yan, C., Jeong, P., Kim, Y. H., Lee, I. S., et al. (2016). Metabolic pathway signatures associated with urinary metabolite biomarkers differentiate bladder cancer patients from healthy controls. Yonsei Medical Journal, 57(4), 865–871.

KO (KEGG ORTHOLOGY) Database. https://www.genome.jp/kegg/ko.html .

Krämer, A., Green, J., Pollard, J., Jr., & Tugendreich, S. (2014). Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics, 30(4), 523–530.

Kuriakose, T., Rada, B., & Watford, W. T. (2014). Tumor progression locus 2-dependent oxidative burst drives phosphorylation of extracellular signal-regulated kinase during TLR3 and 9 signaling. Journal of Biological Chemistry, 289(52), 36089–36100.

Lee, M., Cho, T., Jantaratnotai, N., Wang, Y. T., McGeer, E., & McGeer, P. L. (2010). Depletion of GSH in glial cells induces neurotoxicity: Relevance to aging and degenerative neurological diseases. The FASEB Journal, 24(7), 2533–2545.

Lin, W. T., Yang, S. C., Tsai, S. C., Huang, C. C., & Lee, N. Y. (2006). L-Arginine attenuates xanthine oxidase and myeloperoxidase activities in hearts of rats during exhaustive exercise. British Journal of Nutrition, 95(1), 67–75.

Liu, X., Cheng, X., Liu, X., He, L., Zhang, W., Wang, Y., et al. (2018). Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery. International Journal of Cancer, 143(2), 408–418.

Machine Learning at Waikato University. https://www.cs.waikato.ac.nz/ml/index.html .

McDunn, J. E., Perichon, R., Neri, B., & Wittmann, B. (2015). Biomarkers for bladder cancer and methods using the same. US Patent. Pub. No.: US 2015/0065366 A1, 3/5/2015. https://patentimages.storage.googleapis.com/42/d3/37/b454c930e66f77/US20150065366A1.pdf

MetaboAnalyst—statistical, functional and integrative analysis of metabolomics data. http://www.metaboanalyst.ca/ .

Mpanga, A. Y., Siluk, D., Jacyna, J., Szerkus, O., Wawrzyniak, R., Markuszewski, M., et al. (2018). Targeted metabolomics in bladder cancer: From analytical methods development and validation towards application to clinical samples. Analytica Chimica Acta, 1037, 188–199.

Nakamura, Y., Katagiri, T & Nakatsuru, S. (2012). Method of diagnosing bladder cancer. US Patent 7998695B2.

Oliveros, J.C. (2007–2015) VENNY. An interactive tool for comparing lists with Venn Diagrams. Venny 2.1. http://bioinfogp.cnb.csic.es/tools/venny/index.html .

Pasikanti, K. K., Esuvaranathan, K., Hong, Y., Ho, P. C., Mahendran, R., Raman Nee Mani, L., et al. (2013). Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry. Journal of Proteome Research, 12(9), 3865–3873. https://doi.org/10.1021/pr4000448 .

Perroud, B., Lee, J., Valkova, N., Dhirapong, A., Lin, P. Y., Fiehn, O., et al. (2006). Pathway analysis of kidney cancer using proteomics and metabolic profiling. Molecular Cancer, 5, 64.

Poirion, B. O., Chaudhary, K., & Garmire, L. X. (2018). Deep learning data integration for better risk stratification models of bladder cancer. AMIA Joint Summits on Translational Science Proceedings, 2017, 197–206.

Priolo, C., Pyne, S., Rose, J., Regan, E. R., Zadra, G., Photopoulos, C., et al. (2014). AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Research, 74(24), 7198–7204.

Puchades-Carrasco, L., Jantus-Lewintre, E., Pérez-Rambla, C., García-García, F., Lucas, R., Calabuig, S., et al. (2016). Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer. Oncotarget, 7(11), 12904–12916.

Rodrigues, D., Jeronimo, C., Henrique, R., Belo, L., de Lourdes Basto, S. M., & de Pinho, P. G. (2016). Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems. International Journal of Cancer, 139(2), 256–268.

Sahu, D., Lotan, Y., Wittmann, B., Neri, B., & Hansel, D. E. (2017). Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. Cancer Medicine, 6(9), 2106–2120.

Schoeppner, H. L., Raz, A., Ho, S. B., & Bresalier, R. S. (1995). Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer, 75(12), 2818–2826.

Shen, C., Sun, A., Chen, D., Su, X., Jiang, J., Li, G., et al. (2015). Developing urinary metabolomic signatures as early bladder cancer diagnostic markers. OMICS: A Journal of Integrative Biology, 19(1), 1–11.

Shyh-Chang, N., Locasale, J. W., Lyssiotis, C. A., Zheng, Y., Teo, R. Y., Ratanasirintrawoot, S., et al. (2013). Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science, 339(6116), 222–226.

Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1), 7–30.

Srivastava, S., Roy, R., Singh, S., Kumar, P., Dalela, D., Sankhwar, S. N., et al. (2010). Taurine—a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy. Cancer Biomarkers, 6(1), 11–20.

Tetko, I. V., Gasteiger, J., Todeschini, R., Mauri, A., Livingstone, D., Ertl, P, et al. (2005). Virtual computational chemistry laboratory—design and description. Journal of Computer Aided Molecular Design, 19, 453–463. VCCLAB, Virtual Computational Chemistry Laboratory. http://www.vcclab.org .

Tibbles, L. A., & Woodgett, J. R. (1999). The stress-activated protein kinase pathways. Cellular and Molecular Life Sciences, 55(10), 1230–1254.

Tsigelny, I. F. (2018). Artificial intelligence in drug combination therapy. Briefings in Bioinformatics, bby004, https://doi.org/10.1093/bib/bby004 .

Venn, J. (1880). On the employment of geometrical diagrams for the sensible representations of logical propositions. Proceedings of the Cambridge Philoophical Society, 4, 47–59.

von Rundstedt, F. C., Rajapakshe, K., Ma, J., Arnold, J. M., Gohlke, J., Putluri, V., et al. (2016). Integrative pathway analysis of metabolic signature in bladder cancer: A linkage to the cancer genome atlas project and prediction of survival. Journal of Urology, 195(6), 1911–1919.

Wang, Y., Zhao, F., Jin, Y., Zhong, Y., Yu, X., Li, G., et al. (2011). Effects of exogenous glutathione on arsenic burden and NO metabolism in brain of mice exposed to arsenite through drinking water. Archives of Toxicology, 85(3), 177–184.

Wartenberg, M., Ling, F. C., Schallenberg, M., Bäumer, A. T., Petrat, K., Hescheler, J., et al. (2001). Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. Journal of Biological Chemistry, 276(20), 17420–17428.

Weka 3: Data Mining Software in Java. https://www.cs.waikato.ac.nz/ml/weka/index.html .

Welcome to HMDB Version 4.0. Retrieved October 23, 2018 http://www.hmdb.ca/ .

Whitten, H., Frank, E., Hall, M. & Pal, C. J. (2016). Data Mining: Practical Machine Learning Tools and Techniques (4th ed., pp. 553–572). Morgan Kaufmann Publishers, Inc., Cambridge, Mass., USA; The WEKA Workbench. Appendix B.

Wishart, D. S., Feunang, Y. D., Marcu, A., Guo, A. C., Liang, K., Vázquez-Fresno, R., et al. (2018). HMDB 4.0—The Human Metabolome Database for 2018. Nucleic Acids Research, 46(D1), D608–D617.

Wittmann, B. M., Stirdivant, S. M., Mitchell, M. W., Wulff, J. E., McDunn, J. E., Li, Z., et al. (2014). Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS ONE, 9(12), e115870.

Wu, H., Liu, T., Ma, C., Xue, R., Deng, C., Zeng, H., et al. (2011). GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Analytical and Bioanalytical Chemistry, 401(2), 635–646.

Yigiter, M., Halici, Z., Odabasoglu, F., Keles, O. N., Atalay, F., Unal, B., et al. (2011). Growth hormone reduces tissue damage in rat ovaries subjected to torsion and detorsion: Biochemical and histopathologic evaluation. European Journal of Obstetrics & Gynecology and Reproductive Biology, 157(1), 94–100.

Zaravinos, A., Pieri, M., Mourmouras, N., Anastasiadou, N., Zouvani, I., Delakas, D., et al. (2014). Altered metabolic pathways in clear cell renal cell carcinoma: A meta-analysis and validation study focused on the deregulated genes and their associated networks. Oncoscience, 1(2), 117–131.

Zhao, J., Xu, W., He, M., Zhang, Z., Zeng, S., Ma, C., et al. (2016). Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent copy number variation in IPO11 and prognostic significance of importin-11 overexpression on poor survival. Oncotarget, 7(46), 75648–75658.

Zhou, Y., Song, E., Ma, C., Zhou, L., Liu, X., Yin, P., et al. (2017). Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method. Oncotarget, 8(13), 20719–20728.

Zhu, Y., Bian, X. J., Ye, D. W., Yao, X. D., Zhang, S. L., Dai, B., et al. (2014). Long noncoding RNA expression signatures of bladder cancer revealed by microarray. Oncology Letters, 7(4), 1197–1202.